$7.11
0.17[2.45%]
At close: May 24
$7.11
0[0.00%]
After Hours: 7:28PM EDT
Prime Medicine
(NASDAQ:PRME)Prime Medicine Stock (NASDAQ:PRME), Analyst Ratings, Price Targets, Predictions
Prime Medicine Inc has a consensus price target of $15.86, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Citigroup, and JP Morgan on May 20, 2024, May 16, 2024, and May 13, 2024. With an average price target of $11.67 between HC Wainwright & Co., Citigroup, and JP Morgan, there's an implied 64.09% upside for Prime Medicine Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citigroup
JP Morgan
Jefferies
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Prime Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2024 | Buy Now | 40.65% | HC Wainwright & Co. | Arthur He | → $10 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 40.65% | Citigroup | Samantha Semenkow | → $10 | Upgrade | Neutral → Buy | Get Alert |
| 05/13/2024 | Buy Now | 110.97% | JP Morgan | Eric Joseph | $16 → $15 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | 110.97% | Jefferies | Maury Raycroft | $23 → $15 | Assumes | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 68.78% | Wedbush | David Nierengarten | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 139.1% | Chardan Capital | Geulah Livshits | → $17 | Initiates | → Buy | Get Alert |
| 04/08/2024 | Buy Now | — | TD Cowen | Joseph Thome | — | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 68.78% | Wedbush | David Nierengarten | → $12 | Initiates | → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 68.78% | Wedbush | David Nierengarten | → $12 | Initiates | → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 181.29% | Guggenheim | Debjit Chattopadhyay | $24 → $20 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 40.65% | Citigroup | Samantha Semenkow | → $10 | Initiates | → Neutral | Get Alert |
| 11/07/2023 | Buy Now | 265.68% | JP Morgan | Eric Joseph | $27 → $26 | Maintains | Overweight | Get Alert |
| 10/09/2023 | Buy Now | 167.23% | BMO Capital | Kostas Biliouris | → $19 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 181.29% | JonesTrading | Justin Walsh | → $20 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 167.23% | Morgan Stanley | Matthew Harrison | $21 → $19 | Maintains | Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | 237.55% | Guggenheim | Debjit Chattopadhyay | → $24 | Initiates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 153.16% | Stifel | Dae Gon Ha | → $18 | Initiates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 195.36% | Morgan Stanley | Matthew Harrison | $23 → $21 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 279.75% | JP Morgan | Eric Joseph | → $27 | Initiates | → Overweight | Get Alert |
| 11/14/2022 | Buy Now | 251.62% | Jefferies | Eun Yang | → $25 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 223.49% | Morgan Stanley | Matthew Harrison | → $23 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 209.42% | Goldman Sachs | Salveen Richter | → $22 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Prime Medicine (PRME)?
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by HC Wainwright & Co. on May 20, 2024. The analyst firm set a price target for $10.00 expecting PRME to rise to within 12 months (a possible 40.65% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prime Medicine (PRME)?
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by HC Wainwright & Co., and Prime Medicine initiated their buy rating.
When was the last upgrade for Prime Medicine (PRME)?
The last upgrade for Prime Medicine Inc happened on May 16, 2024 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Prime Medicine Inc.
When was the last downgrade for Prime Medicine (PRME)?
There is no last downgrade for Prime Medicine.
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on May 20, 2024 so you should expect the next rating to be made available sometime around May 20, 2025.
Is the Analyst Rating Prime Medicine (PRME) correct?
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $10.00. The current price Prime Medicine (PRME) is trading at is $7.11, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.